- Molecular NamePhenmetrazine
- Synonym2-Phenyl-3-Methylmorpholine; 3-Methyl-2-phenylmorpholine; Defenmetrazin; Dexphenmetrazine; Fenmetrazin; Fenmetrazina [INN-Spanish]; Oxazimedrine; Phenmetraline hydrochloride; Phenmetrazinum [INN-Latin]; USAF Ge-1
- Weight177.247
- Drugbank_IDDB00830
- ACS_NO134-49-6
- Show 3D model
- LogP (experiment)1.5
- LogP (predicted, AB/LogP v2.0)1.58
- pka8.4 (25°)
- LogD (pH=7, predicted)0.27
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.45
- LogSw (predicted, AB/LogsW2.0)8.49
- Sw (mg/ml) (predicted, ACD/Labs)13.42
- No.of HBond Donors1
- No.of HBond Acceptors2
- No.of Rotatable Bonds1
- TPSA21.26
- StatusFDA approved
- AdministrationOral, Intravenous, Vaporized, Insufflated, Suppository
- PharmacologyA stimulant drug of the morpholine chemical class that was previously used as an appetite suppressant, but has since been withdrawn from the market. It was initially replaced by its analogue phendimetrazine which functions as a prodrug to phenmetrazine, but now it is rarely prescribed either, due to concerns of abuse and addiction.
- Absorption_valueN/A
- Absorption (description)Readily absorbed from the gastro-intestinal tract and buccal mucosa.
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmPrimarily hepatic (via CYP3A and CYP2D6). Resistant to metabolism by monoamine oxidase. Metabolism involves deamination to para-hydroxyamphetamine and phenylacetone; this latter compound is subsequently oxidize to benzoic acid and excreted as glucuronide or glycine (hippuric acid) conjugate. Smaller amounts of amphetamine are converted to norephedrine by oxidation.
- Half life8 h
- ExcretionRenal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of overdose include acute central nervous system stimulation, cardiotoxicity causing tachycardia, arrhythmias, hypertension, and cardiovascular collapse.
- LD50 (rat)N/A
- LD50 (mouse)N/A